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INTRODUCTION
Despite advances in perioperative care, cardiac surgery 
continues to be associated with complications such as myo-
cardial infarction and major adverse cardiovascular events 
that have negative effects on patient outcomes. Historically, 
anesthetics have not been considered beneficial in terms of 
cardiovascular function and myocardial protection. Volatile 
anesthetics have long been thought to depress myocardial 
contractility and vasodilation in a dose-dependent manner. 
In addition, they are suspected of eliciting coronary steal, 
which may aggravate ischemic heart disease. Clinically, how-
ever, these effects remain unproven. By contrast, it is now 
widely perceived that well-balanced anesthesia has favorable 
impacts on myocardial oxygen supply/demand in patients 
with ischemic heart disease by attenuating the maladaptive 
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Cardiac surgery is still associated with complications such as adverse perioperative car-
diovascular events. Over the past two decades, many studies have shown that volatile 
anesthetics and opioids provide myocardial protection against ischemia-reperfusion 
injury in a similar manner as ischemic conditioning. First (1–2 hours) and second (24–72 
hours) windows of protection are provided, the underlying mechanisms for which involve 
activation of G-protein-coupled receptors, protein kinases, and the opening of adenosine 
triphosphate-sensitive potassium channels. These processes ultimately result in inhibi-
tion of the mitochondrial permeability transition pore. Post-conditioning can also be ef-
fective when treatment is applied in the proximity of reperfusion. Although propofol lacks 
these conditioning effects, it acts as a strong antioxidant and protects the myocardium 
by attenuating oxidative stress related to reperfusion injury. Clinical evidence favors the 
use of volatile anesthetics over propofol in terms of reduced cardiac enzyme release, 
length of hospital stay, and mortality. However, the existing evidence level is insufficient 
to draw a definite conclusion regarding the mortality benefit of one anesthetic over the 
others. In addition, many common clinical conditions, such as advanced age, hypergly-
cemia/diabetes, and hypertrophy, have been shown to mitigate the protective efficacy 
of the anesthetics, although this effect also lacks clinical validation. Propofol may also 
abolish the protective effects of volatile anesthetics and opioids by scavenging reactive 
oxygen species, an essential trigger for pre-conditioning. The following review addresses 
these issues from a clinical perspective. 
Key Words: Analgesics, opioid, Anesthetics, inhalation, Myocardial ischemia, Propofol, 
Reperfusion injury.
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sympathetic response. Moreover, anesthetics have been 
shown to have direct myocardial protective effects providing 
tolerance to ischemia-reperfusion (I-R) injury [1]. Anesthetics 
have also been shown to enable better myocardial functional 
recovery in terms of contractile function and arrhythmia after 
I-R injury [2].
Among the various anesthetics in current use, volatile 
anesthetics have been experimentally shown to have the 
most beneficial influence in terms of reducing infarct size 
against myocardial I-R injury via pre- and post-conditioning 
effects [2,3]. Propofol and opioids have also been shown to 
provide myocardial protection against I-R injury by both 
similar and different mechanisms of actions compared to 
volatile anesthetics [4,5]. With the advent of sophisticated 
target-controlled infusion models, along with the favorable 
pharmacokinetic profiles of propofol and remifentanil, total 
intravenous anesthesia (TIVA) has gained increased popu-
larity in cardiac anesthesia. Thus, the anesthetic regimen for 
cardiac surgery has changed from high-dose narcotic-based 
ones to balanced anesthesia using either volatile anesthetics 
or propofol in combination with opioids. However, the ideal 
choice of anesthetics remains to be validated.
The present review article discusses the underlying mecha-
nisms of action by which each anesthetic confers myocardial 
protection, the evidence regarding their clinical utility and 
drawbacks, potential interactions between anesthetics, and 
future clinical perspectives regarding their use and valida-
tion.
MYOCARDIAL PROTECTION VIA 
CONDITIONING INDUCED  
BY VOLATILE ANESTHETICS 
Anesthetic pre-conditioning
Since the introduction of the evolutionary concepts of pre- 
and post-conditioning, numerous therapies providing myo-
cardial protection have been experimentally evaluated. How-
ever, there has been limited success in the clinical translation 
of these therapies. Among experimentally proven methods, 
ischemic pre-conditioning has yielded the most consistent 
results regarding infarct size reduction across various animal 
species in different myocardial I-R injury models. While early 
translational studies have shown promising results, ischemic 
pre-conditioning is not always feasible in clinical settings. 
In 1997, Kersten et al. [1] demonstrated that similar infarct 
size reduction could be obtained with isoflurane, which 
later led to the widely accepted concept of anesthetic pre-
conditioning. Numerous subsequent studies have addressed 
anesthetic pre-conditioning effects on the myocardium using 
enflurane, isoflurane, sevoflurane, and desflurane, aiming to 
also elucidate the underlying mechanisms for such effects. 
Thus far, evidence suggests that anesthetic pre-conditioning 
shares fundamental characteristics with ischemic pre-condi-
tioning, providing early and delayed windows of myocardial 
protection [6,7]. In addition, anesthetic and ischemic pre-
conditioning share many of the same molecular processes in-
volved in myocardial protection, such as G-protein-coupled 
cell membrane receptors, mediation via multiple protein 
kinases, and the opening of adenosine triphosphate-sensitive 
potassium (KATP) channels [2,6,7].
In anesthetic pre-conditioning, as in ischemic pre-
conditioning, the first window of protection is provided for 
approximately 1–2 hours via various cytosolic signaling path-
ways, including reperfusion injury salvage kinase (RISK) and 
survivor-activating factor enhancement (SAFE) pathways. 
The RISK pathway is activated mainly by G-protein-coupled 
cell surface receptors that activate phosphatidylinositol 
(4,5)-biphosphate 3-kinase (PI3K), protein kinase B, and ex-
tracellular-regulated kinase to promote cell survival [8]. The 
SAFE pathway mainly involves tumor necrosis factor (TNF)-a 
and signal transducer and activator of transcription (STAT)-
3 to attenuate apoptotic cell death [9]. Both pathways are also 
known to have close interactions with each other, and with 
either pathway, protection in the mitochondria is conveyed 
by the inhibition of mitochondrial permeability transition 
pore (mPTP) and the activation (opening) of the KATP chan-
nel [10,11]. The second window of protection appears after 
24–48 hours, and lasts up to 72 hours. It involves increased 
expression of protective proteins in response to acute signal-
ing, including protein kinase C (PKC)-e, STAT, and nuclear 
factor-kB [2]. Major upregulated proteins involved in delayed 
myocardial protection include inducible nitric oxide syn-
thase, cyclooxygenase-2, superoxide dismutase, aldose re-
ductase, and heme oxygenase. It has also been suggested that 
activation of sarcolemmal KATP, along with the mitochondrial 
KATP channel, subsequently alleviates cytosolic calcium over-
load in the second window of protection [12,13].
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Importance of mitochondrial mechanisms:  
the mPTP and KATP channel
It is noteworthy that the mitochondria are the molecu-
lar center for various cardioprotective signaling processes, 
and mPTP is a major point of convergence for these various 
signals. Indeed, opening of mPTP during reperfusion is del-
eterious in terms of cell survival. Transient opening of mPTP 
may be a physiological function related to the homeostasis 
of reactive oxygen species (ROS) and calcium release, which 
has been shown to provide cardioprotection during ischemic 
pre-conditioning [12]. However, prolonged opening of mPTP 
results in matrix swelling, rupture of the mitochondrial mem-
brane, and the release of proapoptotic cytochrome C into 
the cytosol, where it triggers apoptotic cell death. Therefore, 
mPTP inhibition is critical in modulating the balance of the 
cell-survival and apoptotic pathways [10].
The mitochondrial KATP channel is a critical determinant 
of mitochondria respiration. Its opening induces inner mito-
chondrial membrane depolarization, preserving mitochon-
drial volume and homeostasis. This attenuates excessive 
ROS generation and mitochondrial calcium accumulation, 
provides the optimal milieu for ATP production, and inhibits 
mPTP. This channel is a direct target of volatile anesthetics, 
and is linked to mitochondrial respiration through nicotin-
amide adenine dinucleotide [11]. It also confers protection 
via a positive feedback loop with PKC-e activation [14].
Considering their importance in mediating myocardial 
protection induced by volatile anesthetics, it is critical to elu-
cidate the pathways that initiate or contribute to the activa-
tion of the mitochondrial KATP channel and the inhibition of 
mPTP. Indeed, many co-morbidities, currently used medica-
tions, and the concomitant use of propofol may interfere with 
these mechanisms. In brief, cardioprotective signaling by 
volatile anesthetics is mainly initiated by G-protein-coupled 
cell membrane receptors, which include b1- and b2-adren-
ergic receptors and adenosine-A1 receptor [2,7]. The role of 
adrenergic receptors seems to be of particular importance in 
desflurane-induced pre-conditioning [15].
The generation of a small amount of ROS is essential in trig-
gering myocardial protection induced by volatile anesthetics, 
while excessive oxidative stress and the production of large 
amounts of ROS are harmful [16]. Volatile anesthetics cause 
a small degree of subclinical harm (e.g., ROS generation) to 
trigger protective signaling against persistent and clinically 
harmful I-R injury, which can be viewed as pre-conditioning. 
Consequently, volatile anesthetics attenuate the generation 
of excessive ROS production after I-R, and thus alleviate the 
hazardous oxidative stress that triggers reperfusion injury 
[17]. 
Anesthetic post-conditioning and other direct 
cardioprotective effects
Volatile anesthetics also provide post-conditioning effects, 
with efficacies similar to those of pre-conditioning in terms of 
reducing infarct size, when given within the first 30 seconds of 
reperfusion [18]. Myocardial protection is not observed when 
post-conditioning with volatile anesthetics is performed 
3–10 minutes after the onset of reperfusion. The underlying 
mechanisms are similar to those of pre-conditioning, and 
involve the activation of G-protein-coupled cell membrane 
receptors and the stimulation of downstream pathways. As in 
pre-conditioning, the major pathways involved are the RISK 
and SAFE pathways. These ultimately inhibit the opening of 
the mPTP, which is thought to be achieved mainly by PKC 
(particularly PKC-e, which is involved in the activation of mi-
tochondrial KATP channel) [2,7].
Apart from their pre- or post-conditioning effects, vola-
tile anesthetics also provide direct endothelial protection 
that may also be linked to myocardial protection. Volatile 
anesthetics attenuate the degradation of the endothelial gly-
cocalyx layer following I-R injury [19], the integrity of which 
plays a vital role in preventing leukocyte and platelet adhe-
sion thereby mitigating inflammation and tissue edema [20]. 
Various experiments, including some performed in human 
umbilical vein tissue, have demonstrated inhibition of the 
expression of TNF-a-induced adhesion molecule by volatile 
anesthetics that may facilitate further recruitment of inflam-
matory cells [21]. 
MYOCARDIAL PROTECTION  
BY OPIOIDS AND PROPOFOL 
Opioids
Opioids have long been favored in cardiac anesthesia for 
their negligible direct myocardial depressant effects in the 
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clinical dose range, apart from their central vagotonic ef-
fects. Even in terms of pharmacokinetics, the modern opioid 
congeners sufentanil and remifentanil do not interfere with 
early awakening of the patient after surgery. Thus they enable 
fast-track anesthesia, if necessary. The role of endogenous 
opioid peptides (such as enkephalins, dynorphins, and en-
dorphins) as anti-inflammatory factors in response to stress 
has long been acknowledged [22]. The role of G-protein-
coupled opioid receptors in conveying the protective signal-
ing in ischemic pre-conditioning of the myocardium has 
also been scrutinized [12]. Of note, externally administered 
opioids have also been shown to provide myocardial protec-
tion against I-R injury in a manner mimicking the effects of 
ischemic pre-conditioning [5].
Molecular pathways involved in opioid-induced myocar-
dial protection are conveyed mostly through d and k opioid 
receptors. Downstream signaling is relayed by G-protein-
coupled signal transduction, PKCs, and PI3K, similar to the 
mechanisms of pre-conditioning induced by volatile anes-
thetics. As with volatile anesthetics, early and late windows 
of myocardial protection are provided, with similar mecha-
nisms and time frames [23]. The first window of protection 
is ultimately provided by the activation of the mitochondrial 
KATP channel and the inhibition of mPTP, whereas the second 
window of protection requires modulation of cardiopro-
tective transcription factors and the expression of relevant 
genes. Notably, small bursts of ROS production due to the 
opening of the mitochondrial KATP channel seem to be as 
pivotal in the further induction and amplification of opioid-
induced cardioprotective signaling as they are in ischemic 
and volatile anesthetic induced pre-conditioning [24]. In ad-
dition, opioids have post-conditioning effects when admin-
istered in close proximity to reperfusion [25]. The underlying 
mechanisms share many of the signaling processes involved 
in pre-conditioning, which ultimately lead to the opening of 
the mitochondrial KATP channel and the inhibition of mPTP 
[23].
Because opioid-induced myocardial protection shares 
many of the features related to ischemic pre-conditioning 
and pre-conditioning induced by volatile anesthetics, it is 
also subject to potential abrogation by advanced age, diabe-
tes/hyperglycemia, and myocardial hypertrophy. Indeed, ex-
perimental data have demonstrated negative changes in opi-
oid receptor responses related to pre- and post-conditioning 
with age and the aforementioned comorbidities [26].
Propofol
Compared to volatile anesthetics, propofol may preserve 
myocardial contractility and the arrhythmogenic threshold at 
clinically relevant concentrations [27]. Along with its pharma-
cokinetic advantage of providing a reliable context-sensitive 
half-life and its superb antiemetic properties, TIVA consisting 
of propofol and remifentanil has rapidly gained interest as an 
anesthetic technique for cardiac surgery, particularly in con-
junction with fast-track anesthesia.
On the other hand, propofol may act as a mitochondrial 
toxin by interfering with oxidative phosphorylation and 
electron transport in a dose-dependent manner, resulting 
in the inhibition of ATP synthesis [28]. Although rare, these 
potentially adverse features are present in propofol infusion 
syndrome, which mimics mitochondrial myopathies caused 
by the disruption of fatty-acid oxidation and the respira-
tory chain [29]. Nonetheless, propofol has consistently been 
shown experimentally to provide cardioprotection against 
I-R injury [4,30].
Propofol is similar in structure to phenol-based radical 
scavengers such as the endogenous antioxidant vitamin E. 
Excessive ROS generation related to myocardial I-R, rep-
resenting oxidative stress, plays a critical role in the patho-
genesis of myocardial contractile dysfunction, dysrhythmia, 
microvascular damage, and cell death either by necrosis 
or apoptosis [31]. In that context, propofol acts as a strong 
antioxidant. It scavenges oxygen free radicals through the 
formation of phenoxy radicals, which is the key mechanism 
involved in propofol-induced myocardial protection against 
I-R injury [4,30]. It also provides mitochondrial membrane 
stabilization via decreased mitochondrial calcium uptake 
and direct inhibition of mPTP [32]. In contrast to volatile an-
esthetics and opioids, its mechanism of action suggests that 
it does not trigger signaling pathways related to pre- or post-
conditioning, and thus lacks any conditioning effect in terms 
of myocardial protection against I-R injury [33]. Propofol’s 
ability to preserve myocardial function after I-R injury may be 
attributable to the compensatory hypercontractile state of the 
non-ischemic region, whereas isoflurane is able to preserve 
the contractile function in the ischemic region [34]. Overall, 
the degree of myocardial protection against I-R injury provid-
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ed by propofol seems to be somewhat less than that of pre-
conditioning induced by volatile anesthetics [6,7].
CLINICAL TRANSLATION OF 
EXPERIMENTAL DATA
Based on experimental data, anesthetic conditioning has 
been translated into clinical practice, mostly in the cardiac 
surgical setting. While a number of studies with limited 
sample sizes have reported beneficial effects of volatile anes-
thetics in terms of myocardial enzyme release, function re-
covery, and length of hospital stay, there is not yet conclusive 
evidence to support a reduction in mortality. The two largest 
randomized controlled trials conducted to date involved 414 
patients (De Hert et al. [35]) and 868 patients (Likhvantsev 
et al. [36]) undergoing coronary artery bypass graft surgery 
(CABG). De Hert et al. [35] compared sevoflurane or desflu-
rane administered at > 0.5 minimum alveolar concentration 
(MAC) to propofol in a multicenter, randomized trial, and 
found no difference in postoperative peak troponin T levels 
associated with the anesthetic regimen. However, they ob-
served reduced length of hospital stay in the volatile anes-
thetic group compared to the propofol group, and reduced 
1-year mortality for sevoflurane (3.3%) and desflurane (6.7%) 
versus propofol (12.3%). Likhvantsev et al. [36] compared 
sevoflurane to propofol administered via bispectral index 
score guidance (between 40–60) in a multicenter, random-
ized trial, and reported reduced length of hospital stay, tro-
ponin T release, and 1-year mortality (17.8% vs. 24.8%) in the 
sevoflurane group versus the propofol group. However, their 
mortality rates were unconventionally high, considering that 
the median EuroSCORE II of the patients ranged from 0.75 to 
0.77.
Not surprisingly, meta-analyses including mainly small 
single-center studies of volatile anesthetics [37–40] have 
found conflicting results. The most recent meta-analysis [38] 
involved 3,966 patients from 38 trials, and reported a signifi-
cant 50% reduction in mortality (1.3% vs. 2.6%) in the volatile 
anesthetic group versus the propofol group. Other meta-
analyses have reported 47% reductions in myocardial infarc-
tion, 69% reductions in postoperative inotrope use [37], and 
36.6% reductions in cardiac enzyme release [39].
Two longitudinal retrospective studies have been carried 
out, in Italy (n = 34,310) [41] and Denmark (n = 10,535) [42]. 
They included patients undergoing only CABG and CABG 
plus other cardiac surgeries, respectively. Both studies sug-
gested that reduced mortality was associated with the use 
of volatile anesthetics. However, the results of these studies 
were inconsistent: the Italian study demonstrated a reduced 
risk-adjusted mortality rate with the use of volatile anesthet-
ics versus TIVA, while only isoflurane was associated with 
reduced mortality, not sevoflurane or desflurane [41]. In the 
Danish study [42], overall 30-day mortality was lower in a 
sevoflurane group compared to a TIVA group, but the results 
were not statistically significant (2.84% vs. 3.30%, P = 0.18). 
Statistically significant mortality benefits of sevoflurane ver-
sus TIVA were observed only in patients without unstable 
angina or recent myocardial infarction. Conversely, the 
mortality rate was similar between the anesthetics in patients 
with unstable angina or recent myocardial infarction, which 
indicates no additive protection by volatile conditioning to 
the ischemic conditioning. Interestingly, urgent CABG sur-
gery was associated with six-fold higher mortality than elec-
tive CABG, and propofol was associated with significantly 
lower mortality compared to the sevoflurane in this subset of 
patients (8.19% vs. 16.23%, P = 0.031). 
Nevertheless, no large-scale, multicenter, randomized tri-
als have clearly demonstrated that volatile anesthetics reduce 
mortality. Such studies would require a large number of pa-
tients (at least 5,000, assuming a mortality rate of 2%) consid-
ering the current low mortality rate in developed countries. 
Furthermore, the data mainly involve CABG patients, and 
ischemic symptoms before surgery may mimic ischemic 
pre-conditioning, confounding the observed results [42]. Evi-
dence is even more scarce for patients without coronary ar-
tery disease undergoing cardiac surgeries other than CABG.
Major drawbacks limiting the clinical efficacy of volatile an-
esthetics include co-morbidities and associated medications. 
Most experimental evidence has been collected using young 
animals without any co-morbid diseases. Indeed, advanced 
age, concentric hypertrophy, diabetes, and the presence of 
transient hyperglycemia (commonly encountered features 
in the cardiac surgical setting) have all been experimentally 
shown to abolish the cardioprotective effects of volatile anes-
thetics [7]. In addition to the well-known negative effects of 
sulfonylurea on anesthetic preconditioning, the use of beta-
blockers has also been shown to mitigate myocardial protec-
tion, while the use of angiotensin-converting enzyme inhibi-
Anesthetics and myocardial protection
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tors/angiotensin receptor blockers may enhance protection 
[12]. The interactions among these conditions and medica-
tions have not yet been clinically validated; for example, b-
blockers do not seem to interfere with volatile-induced anes-
thetic conditioning clinically [43].
Another major drawback is the lack of an established 
consensus regarding the dosing or administration protocol 
for anesthetics. Even in experimental studies, there are con-
troversies over the minimum requirement (0.3 vs. 0.5 MAC) 
or the administration protocol (multiple versus single cycle 
with wash-out periods versus continuous administration) 
[6,7]. Experimental evidence suggests that there exists a dose-
response effect with a ceiling effect reached at 2 MAC [44]. 
Clinically, however, the administration of 2 MAC volatile 
anesthetics may not be feasible in cardiac surgical patients 
without the concomitant use of adrenergic stimulants, which 
may compromise anesthetic pre-conditioning. Clinical 
evidence is also inconclusive regarding the optimal admin-
istration protocol. Two studies involving small numbers of 
patients undergoing CABG advocated the use of multiple 
cycles of volatile anesthetic administration, interspersed with 
wash-out periods to attenuate myocardial damage [45,46]. 
However, concerns were raised regarding the potential delay 
of cardiopulmonary bypass required to wait for the wash-
out period. More importantly, providing wash-out periods 
may not be feasible as anesthesia must be ensured to patients 
throughout the surgery. Nonetheless, the use of volatile anes-
thetics in a practical manner (e.g., guided by bispectral index 
score) has beneficial effects in patients undergoing CABG [36].
Regarding the use of propofol-based TIVA, it is important 
to note that its oxygen free radical scavenging property may 
actually prevent other pre-conditioning effects [16,24]. In-
deed, one of the triggers of anesthetic pre-conditioning is the 
formation of ROS species that can be inhibited by propofol. 
Accordingly, concomitant use of propofol with volatile an-
esthetics has been shown to abrogate the cardioprotective 
effects of anesthetic pre- and post-conditioning [7]. Clinically, 
the use of propofol may be a major factor mitigating the myo-
cardial protective efficacy of remote ischemic pre-condition-
ing, which shares many protective signaling pathways with 
ischemic or anesthetic pre-conditioning [47]. Likhvantsev et 
al. [36] recently found that avoiding propofol was associated 
with decreased cardiac enzyme release and reduced length 
of hospital stay, even in patients who received propofol at 
anesthetic induction while sevoflurane was administered 
throughout the surgery.
Interestingly, one study has suggested superior myocardial 
protection in patients undergoing CABG using a combination 
of isoflurane before cardiopulmonary bypass and propofol 
thereafter, compared to isoflurane or propofol anesthesia 
alone [48]. Although performed on a small number of pa-
tients, this study implicates the potential for combining pre-
conditioning induced by volatile anesthetics with the free 
radical scavenging properties of propofol. However, volatile 
anesthetics must always be administered before propofol. 
Finally, the use of an opioid (remifentanil) in conjunction 
with volatile anesthetics has been clinically shown to provide 
additive myocardial protection [7,23].
CONCLUSIONS AND PERSPECTIVES
Although the current literature suggests a beneficial role 
for volatile anesthetics over propofol in terms of myocardial 
enzyme release, length of hospital stay, and mortality, the 
level of evidence is insufficient. One must also acknowledge 
emerging evidence for the potential neurotoxicity of vola-
tile anesthetics, particularly in the developing brain and in 
patients with Alzheimer’s disease. By contrast, propofol has 
well-validated antiemetic efficacy and is not known to be as-
sociated with the formation of neurofibrillary tangles or amy-
loid plaques related to the progression of Alzheimer’s disease 
[49]. Therefore, based on current evidence, both anesthetic 
regimens can be employed depending on patients’ comor-
bidities.
Considering that ROS production is essential in trigger-
ing the pre-conditioning effects of volatile anesthetics and 
opioids, it is reasonable to use volatile anesthetics in combi-
nation with opioids before aortic cross-clamp application to 
maximize their pre-conditioning stimuli. TIVA can be used 
after reperfusion to reduce oxidative stress and reperfusion 
injury without hindering the early and late windows of myo-
cardial protection provided by pre-conditioning. In addition, 
it may be beneficial to discontinue oral hypoglycemic agents 
that may interfere with the opening of the mitochondrial 
KATP channel, and to avoid desflurane in patients receiving b-
blockers. In selected patients with acute coronary syndrome 
presenting for urgent or salvage CABG, TIVA may be consid-
ered.
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The optimal regimen for myocardial protection and patient 
outcome must be validated through large-scale, randomized, 
multicenter studies. Likewise, appropriate studies should 
be conducted to determine whether TIVA is more beneficial 
than volatile anesthetics in patients with advanced age, hy-
pertrophy, or diabetes. Above all, we should bear in mind that 
anesthetics cannot prevent myocardial cell death from isch-
emia. They merely delay it by providing increased ischemic 
tolerance; thus, timely reperfusion therapy should always be 
a top priority in cases of suspected myocardial ischemia dur-
ing the perioperative period. 
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